New research builds on evidence that diet, certain brain training exercises and physical activity can delay the decline of ...

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

A ground-breaking study gives those with elevated Alzheimer’s risk a new path for changing the trajectory of their brain health. The researchers reported a significant improvement in global cognition ...

A new result shows that just about anyone at risk for Alzheimer’s – and that’s most of us – can change the trajectory of ...

A major international research effort led by UNSW's Center for Healthy Brain Aging (CHeBA) is reshaping our understanding of ...

Trontinemab's Phase Ib/IIa Brainshuttle AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining Design of the Phase III TR ...

South Korean pharmaceutical and biotech companies are presenting their latest Alzheimer’s research at the world’s largest ...

Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer's Disease ...

Community and research will remain priorities for the Alzheimer’s Association over the next 10 years, Maria Carrillo, PhD, ...

Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases.

A new study shows that the way amyloid proteins—implicated in Alzheimer's disease—assemble into fibrils can be significantly ...